CAR-T cell therapy has significantly improved outcomes for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). but challenges such as limited resources. manufacturing timelines. and notable toxicities persist. https://www.kingarte.com/product-category/refusegarbage/